Use of confidex to control perioperative bleeding in pediatric heart surgery: Prospective cohort study

Chiara Giorni, Zaccaria Ricci, Francesca Iodice, Cristiana Garisto, Isabella Favia, Angelo Polito, Adriano Carotti, Paola Cogo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bleeding during and after cardiac surgery is a major issue in pediatric patients. A prospective cohort study was conducted to evaluate the effect of a commercially available prothrombin complex (Confidex) administered in cardiac surgery after weaning from cardiopulmonary bypass of infants with nonsurgical bleeding. In this study, 14 patients younger than 1 year received a Confidex bolus and were matched with 11 patients of a similar age who did not receive the drug. The preoperative coagulation profile was similar in the two groups. No side effects, including anaphylaxis or thrombotic events, were observed. The numbers of units of packed red blood cells and fresh frozen plasma administered both intra- and postoperatively were similar. The postoperative coagulation examination results and thromboelastographic parameters did not differ significantly between the two groups. However, the Confidex patients bled significantly less than the control subjects during the first 24 postoperative hours. The median volume of drained blood was 0.0 ml/kg h (range 0-1.9 ml/kg h) compared with 1.9 ml/kg h (range 1-3 ml/kg h) (p = 0.009). At least one unit of packed red blood cells in the postoperative phase was required by 2 patients (14 %) in the Confidex group and six patients (54 %) in the control group (odds ratio [OR], 0.13; 95 % confidence interval [CI], 0.02-0.9; p = 0.03). The median duration of mechanical ventilation was 3 days (range 2-4 days) in the Confidex group and 4 days (range 0-8 days) in the control group (p = 0.66). The median stay in the intensive care unit was 6 days (range 5-9 days) in the Confidex group and 7 days (range 4-12 days) in the control group (p = 0.88). The use of Confidex for infants undergoing cardiac surgery was safe and effective. It reduced postoperative bleeding and allowed fewer units of packed red blood cells to be infused in the postoperative phase without major side effects.

Original languageEnglish
Pages (from-to)208-214
Number of pages7
JournalPediatric Cardiology
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Thoracic Surgery
Cohort Studies
Prospective Studies
Pediatrics
Hemorrhage
Erythrocytes
Control Groups
Prothrombin
Anaphylaxis
Blood Volume
Cardiopulmonary Bypass
Artificial Respiration
Intensive Care Units
Odds Ratio
Confidence Intervals
Pharmaceutical Preparations

Keywords

  • Blood product
  • Pediatric cardiac surgery
  • Post-operative bleeding
  • Prothrombin concentrate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Use of confidex to control perioperative bleeding in pediatric heart surgery : Prospective cohort study. / Giorni, Chiara; Ricci, Zaccaria; Iodice, Francesca; Garisto, Cristiana; Favia, Isabella; Polito, Angelo; Carotti, Adriano; Cogo, Paola.

In: Pediatric Cardiology, Vol. 35, No. 2, 02.2014, p. 208-214.

Research output: Contribution to journalArticle

@article{9ef60f414fcd41e8be291b24c177d4b7,
title = "Use of confidex to control perioperative bleeding in pediatric heart surgery: Prospective cohort study",
abstract = "Bleeding during and after cardiac surgery is a major issue in pediatric patients. A prospective cohort study was conducted to evaluate the effect of a commercially available prothrombin complex (Confidex) administered in cardiac surgery after weaning from cardiopulmonary bypass of infants with nonsurgical bleeding. In this study, 14 patients younger than 1 year received a Confidex bolus and were matched with 11 patients of a similar age who did not receive the drug. The preoperative coagulation profile was similar in the two groups. No side effects, including anaphylaxis or thrombotic events, were observed. The numbers of units of packed red blood cells and fresh frozen plasma administered both intra- and postoperatively were similar. The postoperative coagulation examination results and thromboelastographic parameters did not differ significantly between the two groups. However, the Confidex patients bled significantly less than the control subjects during the first 24 postoperative hours. The median volume of drained blood was 0.0 ml/kg h (range 0-1.9 ml/kg h) compared with 1.9 ml/kg h (range 1-3 ml/kg h) (p = 0.009). At least one unit of packed red blood cells in the postoperative phase was required by 2 patients (14 {\%}) in the Confidex group and six patients (54 {\%}) in the control group (odds ratio [OR], 0.13; 95 {\%} confidence interval [CI], 0.02-0.9; p = 0.03). The median duration of mechanical ventilation was 3 days (range 2-4 days) in the Confidex group and 4 days (range 0-8 days) in the control group (p = 0.66). The median stay in the intensive care unit was 6 days (range 5-9 days) in the Confidex group and 7 days (range 4-12 days) in the control group (p = 0.88). The use of Confidex for infants undergoing cardiac surgery was safe and effective. It reduced postoperative bleeding and allowed fewer units of packed red blood cells to be infused in the postoperative phase without major side effects.",
keywords = "Blood product, Pediatric cardiac surgery, Post-operative bleeding, Prothrombin concentrate",
author = "Chiara Giorni and Zaccaria Ricci and Francesca Iodice and Cristiana Garisto and Isabella Favia and Angelo Polito and Adriano Carotti and Paola Cogo",
year = "2014",
month = "2",
doi = "10.1007/s00246-013-0760-y",
language = "English",
volume = "35",
pages = "208--214",
journal = "Pediatric Cardiology",
issn = "0172-0643",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Use of confidex to control perioperative bleeding in pediatric heart surgery

T2 - Prospective cohort study

AU - Giorni, Chiara

AU - Ricci, Zaccaria

AU - Iodice, Francesca

AU - Garisto, Cristiana

AU - Favia, Isabella

AU - Polito, Angelo

AU - Carotti, Adriano

AU - Cogo, Paola

PY - 2014/2

Y1 - 2014/2

N2 - Bleeding during and after cardiac surgery is a major issue in pediatric patients. A prospective cohort study was conducted to evaluate the effect of a commercially available prothrombin complex (Confidex) administered in cardiac surgery after weaning from cardiopulmonary bypass of infants with nonsurgical bleeding. In this study, 14 patients younger than 1 year received a Confidex bolus and were matched with 11 patients of a similar age who did not receive the drug. The preoperative coagulation profile was similar in the two groups. No side effects, including anaphylaxis or thrombotic events, were observed. The numbers of units of packed red blood cells and fresh frozen plasma administered both intra- and postoperatively were similar. The postoperative coagulation examination results and thromboelastographic parameters did not differ significantly between the two groups. However, the Confidex patients bled significantly less than the control subjects during the first 24 postoperative hours. The median volume of drained blood was 0.0 ml/kg h (range 0-1.9 ml/kg h) compared with 1.9 ml/kg h (range 1-3 ml/kg h) (p = 0.009). At least one unit of packed red blood cells in the postoperative phase was required by 2 patients (14 %) in the Confidex group and six patients (54 %) in the control group (odds ratio [OR], 0.13; 95 % confidence interval [CI], 0.02-0.9; p = 0.03). The median duration of mechanical ventilation was 3 days (range 2-4 days) in the Confidex group and 4 days (range 0-8 days) in the control group (p = 0.66). The median stay in the intensive care unit was 6 days (range 5-9 days) in the Confidex group and 7 days (range 4-12 days) in the control group (p = 0.88). The use of Confidex for infants undergoing cardiac surgery was safe and effective. It reduced postoperative bleeding and allowed fewer units of packed red blood cells to be infused in the postoperative phase without major side effects.

AB - Bleeding during and after cardiac surgery is a major issue in pediatric patients. A prospective cohort study was conducted to evaluate the effect of a commercially available prothrombin complex (Confidex) administered in cardiac surgery after weaning from cardiopulmonary bypass of infants with nonsurgical bleeding. In this study, 14 patients younger than 1 year received a Confidex bolus and were matched with 11 patients of a similar age who did not receive the drug. The preoperative coagulation profile was similar in the two groups. No side effects, including anaphylaxis or thrombotic events, were observed. The numbers of units of packed red blood cells and fresh frozen plasma administered both intra- and postoperatively were similar. The postoperative coagulation examination results and thromboelastographic parameters did not differ significantly between the two groups. However, the Confidex patients bled significantly less than the control subjects during the first 24 postoperative hours. The median volume of drained blood was 0.0 ml/kg h (range 0-1.9 ml/kg h) compared with 1.9 ml/kg h (range 1-3 ml/kg h) (p = 0.009). At least one unit of packed red blood cells in the postoperative phase was required by 2 patients (14 %) in the Confidex group and six patients (54 %) in the control group (odds ratio [OR], 0.13; 95 % confidence interval [CI], 0.02-0.9; p = 0.03). The median duration of mechanical ventilation was 3 days (range 2-4 days) in the Confidex group and 4 days (range 0-8 days) in the control group (p = 0.66). The median stay in the intensive care unit was 6 days (range 5-9 days) in the Confidex group and 7 days (range 4-12 days) in the control group (p = 0.88). The use of Confidex for infants undergoing cardiac surgery was safe and effective. It reduced postoperative bleeding and allowed fewer units of packed red blood cells to be infused in the postoperative phase without major side effects.

KW - Blood product

KW - Pediatric cardiac surgery

KW - Post-operative bleeding

KW - Prothrombin concentrate

UR - http://www.scopus.com/inward/record.url?scp=84893683972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893683972&partnerID=8YFLogxK

U2 - 10.1007/s00246-013-0760-y

DO - 10.1007/s00246-013-0760-y

M3 - Article

C2 - 23843105

AN - SCOPUS:84893683972

VL - 35

SP - 208

EP - 214

JO - Pediatric Cardiology

JF - Pediatric Cardiology

SN - 0172-0643

IS - 2

ER -